I agree that this site is using cookies. You can find further informations here.
X
Lalezari, Jacob P
149  results:
Search for persons X
?
1

Suppression of human and simian immunodeficiency virus repl..:

Chang, Xiao L. ; Reed, Jason S. ; Webb, Gabriela M....
PLOS Pathogens.  18 (2022)  3 - p. e1010396 , 2022
Link: https://doi.org/10.1371/..
 
?
2

EDP-514, a novel pangenotypic class II hepatitis B virus co..:

Feld, Jordan ; Lawitz, Eric ; Nguyen, Tuan T...
Journal of Hepatology.  77 (2022)  - p. S848 , 2022
Link: https://doi.org/10.1016/..
 
?
3

Deeper virologic suppression with the addition of vebicorvi..:

Sulkowski, Mark S ; Fung, Scott K ; Ma, Xiaoli...
Journal of Hepatology.  77 (2022)  - p. S836-S837 , 2022
Link: https://doi.org/10.1016/..
 
?
4

Disruption of CCR5 signaling to treat COVID-19-associated c..:

Agresti, Nicholas ; Lalezari, Jacob P. ; Amodeo, Phillip P....
Journal of Translational Autoimmunity.  4 (2021)  - p. 100083 , 2021
Link: https://doi.org/10.1016/..
 
?
5

Case study of a critically ill person with COVID-19 on ECMO..:

Elneil, Sohier ; Lalezari, Jacob P. ; Pourhassan, Nader Z.
Journal of Translational Autoimmunity.  4 (2021)  - p. 100097 , 2021
Link: https://doi.org/10.1016/..
 
?
6

On‐treatment HCV RNA as a predictor of sustained virologica..:

Kowdley, Kris V. ; Nelson, David R. ; Lalezari, Jacob P....
Liver International.  36 (2016)  11 - p. 1611-1618 , 2016
Link: https://doi.org/10.1111/..
 
?
7

All‐oral 12‐week treatment with daclatasvir plus sofosbuvir..:

Nelson, David R. ; Cooper, James N. ; Lalezari, Jacob P....
Hepatology.  61 (2015)  4 - p. 1127-1135 , 2015
Link: https://doi.org/10.1002/..
 
?
8

Immunogenicity and Safety of 13-Valent Pneumococcal Conjuga..:

Glesby, Marshall J. ; Watson, Wendy ; Brinson, Cynthia...
The Journal of Infectious Diseases.  212 (2015)  1 - p. 18-27 , 2015
Link: http://www.jstor.org/sta..
 
?
9

Safety and Efficacy of Dolutegravir in Treatment-Experience..:

Eron, Joseph J. ; Clotet, Bonaventura ; Durant, Jacques...
The Journal of Infectious Diseases.  207 (2012)  5 - p. 740-748 , 2012
Link: https://doi.org/10.1093/..
 
?
10

Pharmacokinetics of once-daily Etravirine without and with ..:

DeJesus, Edwin ; Lalezari, Jacob P ; Osiyemi, Olayemi O...
Antiviral Therapy.  15 (2010)  5 - p. 711-720 , 2010
Link: https://doi.org/10.3851/..
 
?
11

Anti-HIV-1 Activity of Weekly or Biweekly Treatment with Su..:

Jacobson, Jeffrey M. ; Thompson, Melanie A. ; Lalezari, Jacob P....
The Journal of Infectious Diseases.  201 (2010)  10 - p. 1481-1487 , 2010
Link: https://www.jstor.org/st..
 
?
12

Anti–HIV‐1 Activity of Weekly or Biweekly Treatment with Su..:

Jacobson, Jeffrey M. ; Thompson, Melanie A. ; Lalezari, Jacob P....
The Journal of Infectious Diseases.  201 (2010)  10 - p. 1481-1487 , 2010
Link: https://doi.org/10.1086/..
 
?
13

Preliminary safety and efficacy data of brecanavir, a novel..:

Lalezari, Jacob P. ; Ward, Douglas J. ; Tomkins, Susan A..
Journal of Antimicrobial Chemotherapy.  60 (2007)  1 - p. 170-174 , 2007
Link: https://doi.org/10.1093/..
 
?
14

T‐1249 Retains Potent Antiretroviral Activity in Patients W..:

Lalezari, Jacob P. ; Bellos, Nicholaos C. ; Sathasivam, Kunthavi...
The Journal of Infectious Diseases.  191 (2005)  7 - p. 1155-1163 , 2005
Link: https://doi.org/10.1086/..
 
?
15

T-1249 Retains Potent Antiretroviral Activity in Patients W..:

Lalezari, Jacob P. ; Bellos, Nicholaos C. ; Sathasivam, Kunthavi...
The Journal of Infectious Diseases.  191 (2005)  7 - p. 1155-1163 , 2005
Link: https://www.jstor.org/st..
 
1-15